TY - JOUR
T1 - Second-generation antipsychotics
T2 - Reviewing the cost-effectiveness component of the CATIE trial
AU - Rosenheck, Robert
AU - Swartz, Marvin
AU - McEvoy, Joseph Patrick
AU - Stroup, T. Scott
AU - Davis, Sonia
AU - Keefe, Richard S.E.
AU - Hsiao, John
AU - Lieberman, Jeffrey
N1 - Funding Information:
Robert Rosenheck reports having received research funding from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb and Eli Lilly and Co.; and consulting fees from Bristol-Myers Squibb, Eli Lilly and Co. and Janssen Pharmaceutica Products. Jeffrey Lieberman reports having received research funding from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica Products and Pfizer Inc.; and consulting and educational fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Eli Lilly and Co., Forest Pharmaceutical Company, GlaxoSmithKline, Janssen Pharmaceutica Products, Novartis, Pfizer Inc. and Solvay. T Scott Stroup reports having received research funding from Eli Lilly and Co.; and consulting fees from Janssen Pharmaceutica Products, GlaxoSmithKline and Bristol-Myers Squibb. Joseph McEvoy reports having received research funding from Astra-Zeneca, Forest Research Institute, Eli Lilly and Co., Janssen Pharmaeutica and Pfizer Inc.; consulting or advisory board fees from Pfizer Inc. and Bristol-Myers Squibb; and lecture fees from Janssen Pharmaceutica, and Bristol-Myers Squibb. Marvin Swartz reports having received research funding from Eli Lilly and Co.; and consulting and educational fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Eli Lilly and Co. and Pfizer Inc. Richard SE Keefe reports having received research funding from AstraZeneca, Eli Lilly and Co. and Jans-sen Pharmaeutica; consulting fees or advisory board payments from Forest Labs, Eli Lilly and Co., Janssen Pharmaceutica, Pfizer Inc. and Bristol-Myers Squibb; and lecture fees from Eli Lilly and Co. and Janssen Pharmaceutica. John Hsaio reports no financial disclosures.
PY - 2007/4
Y1 - 2007/4
N2 - The cost-effectiveness component of the 18-month CATIE trial of schizophrenia ppharmacotherapy (n = 1460) showed that the first-generation antipsychotic pephenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.
AB - The cost-effectiveness component of the 18-month CATIE trial of schizophrenia ppharmacotherapy (n = 1460) showed that the first-generation antipsychotic pephenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.
KW - Antipsychotics
KW - Cost-effectiveness
KW - Quality of life
KW - Randomized trials schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=34247567935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247567935&partnerID=8YFLogxK
U2 - 10.1586/14737167.7.2.103
DO - 10.1586/14737167.7.2.103
M3 - Review article
C2 - 20528436
AN - SCOPUS:34247567935
SN - 1473-7167
VL - 7
SP - 103
EP - 111
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 2
ER -